Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opevesostat PK in Moderate Hepatic Impairment
NCT06860243Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of opevesostat in prostate cancer (PCa), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration Versus Time Curve from 0 to Infinity at 96 hours, Area Under the Concentration Versus Time Curve from 0 to the Last Quantifiable Sample at 96 hours and 6 more. Started May 2025; status: completed.
02
Drugs
opevesostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06860243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860243.